Afamac 20/30/40/50 Tablets
Afamac 20/30/40/50 Tablets - Image 2
Afamac 20/30/40/50 Tablets - Image 3
Afamac 20/30/40/50 Tablets - Image 4
Afamac 20/30/40/50 Tablets - Image 5

Afamac 20/30/40/50 Tablets

Generic Name– Afatinib
Drug Class – Antineoplastic Agent / Tyrosine Kinase Inhibitor (TKI)

Afatinib is an oral chemotherapy drug used for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations, and for certain cases of squamous cell carcinoma of the lung progressing after platinum-based chemotherapy.
It works by irreversibly inhibiting the ErbB family of receptor tyrosine kinases (including EGFR, HER2, and HER4), thereby blocking signal transduction pathways responsible for cancer cell growth and proliferation.
Afatinib is administered orally in tablet form, typically once daily, under the supervision of an oncologist. It may be used as first-line therapy in EGFR mutation–positive NSCLC patients.
Common side effects include diarrhea, rash, stomatitis, decreased appetite, paronychia, and dry skin. Dose adjustments may be required based on tolerance and adverse reactions.

Dosage: Available in 20 mg, 30 mg, 40 mg, and 50 mg tablets

Category: Oral Tablet

Category:

Indications & Usage

Dydrogesterone is indicated for:

  • Prevention of natural abortion in adult patients who have a history of habitual abortions (Threatened or Recurrent Miscarriage)
  • Treatment option for patients with dysmenorrhea (severe and frequent menstrual cramps and pain during the period)
  • Treatment of endometriosis, a condition with abdominal pain and menstrual irregularities as common symptoms

Clinical Efficacy

  • First clinical treatment choice due to its the good oral bioavailability and lesser risk of developing breast or endometrial cancer compared to other progestagens
  • Shown to have significant improvements in pelvic pain, dysmenorrhea and dyspareunia, and a high level of satisfaction in the post-laparoscopic in women with endometriosis
  • More effective than conservative treatment in maintaining pregnancy in women with threatened miscarriage
  • Effectively improves hormone levels and related cellular immune factors in recurrent spontaneous abortion (RSA) patients
  • Regularize menstrual-cycle in women with abnormal uterine bleeding – ovulatory dysfunction

Safety Information

Adverse Reactions

  • The most common adverse events that occurs after administration of dydrogesterone are vaginal hemorrhage, nausea, vomiting, migraines or headaches, abdominal pain, menstrual complaints, and breast pain or tenderness

Contraindications

  • It is contraindicated in patients with a known hypersensitivity to dydrogesterone or any other ingredient present in formulation
  • Undiagnosed vaginal bleeding
  • Treatment for luteal support as part of an Assisted Reproductive Technology (ART) treatment should be discontinued upon diagnosis of abortion/miscarriage
  • Contraindications for the use of estrogens when used in combination with dydrogesterone

Special Precautions

  • The etiology for the bleeding should be clarified before starting the dydrogesterone treatment
  • Use dydrogesterone cautiously in patients with acute liver disease or a history of liver disease, discontinuing in severe cases
  • Breakthrough bleeding and spotting in the initial months of dydrogesterone treatment may warrant investigation, including endometrial biopsy, if they persist or recur after treatment cessation
  • Close supervision is advised for patients with a history of or predisposition to porphyria, or abnormal liver function during pregnancy or previous hormone treatment, considering potential recurrence or aggravation during dydrogesterone treatment, with discontinuation as an option
  • Patients with a history of depression may require vigilant monitoring, and if severe depression reoccurs, dydrogesterone treatment should be discontinued
  • In cases of habitual or threatened abortion, confirm fetal viability and monitor ongoing pregnancy progress and embryo vitality during treatment with dydrogesterone
  • Dydrogesterone has increased metabolism with CYP enzyme inducers (e.g. rifampicin, carbamazepine, phenobarbital, phenytoin, efavirenz, nevirapine)
  • Perform regular physical exams (including breast and pelvic tests, mammograms, blood pressure monitoring and Pap smears) is advised before and during dydrogesterone treatment
  • Dydrogesterone may cause drowsiness or dizziness, especially after intake; use caution when driving or operating machinery

Related products